System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Santiago Quirce is an expert in Immunology at Hospital Universitario La Paz (Spain). As of October 2026, ScienceLeadR ranks Santiago Quirce in the top 1% of experts worldwide for Occupational Diseases, Asthma and Hypersensitivity. Santiago Quirce has authored 679 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 2,069 (community average: 125). How the SLR is computed.

LeadR Profile

Santiago Quirce Hospital Universitario La Paz Spain
2 069 ScienceLeadR Reputation 2069

Unlock

Register Login
Network Map

Immunology

Subspecialties: Pulmonology - Allergy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Hospital Universitario La Paz

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 679

Citations

Citations: 17 182 1st author: 77 Last author: 157 Unique author: 4

Main journals

J Investig Allergol Clin Immunol 116
Allergy 100
J Allergy Clin Immunol 80
Arch Bronconeumol 27
J Allergy Clin Immunol Pract 25

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
New CRS control tests: development and validation by EUFOREA.
PMID 42858245 — nose		Rhinology20260
ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases: An OECD Best Practice for Integrated Care for Chronic Diseases.
PMID 42613592 — change management, intelligence, chronic disease, air, rhinitis, asthma, artificial intelligence		Clin Transl Allergy20260
Prevalence of sensitization to Quercus ilex pollen and its contribution to Pollen Food Allergy Syndrome in Central Spain.
PMID 42517370 — food hypersensitivity, hypersensitivity, allergens, food, prevalence, child, allergy		Eur Ann Allergy Clin Immunol20260
Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.
PMID 42384129 — omalizumab, quality-adjusted life years, therapeutics, asthma		Pharmacoecon Open20260
Rescue Inhaler Overuse in Severe Asthma: A Real-World Study of Short-Acting β 2-Agonist and Short-Acting Muscarinic Antagonist Use.
PMID 42351760 — comorbidity, adrenal cortex hormones, muscarinic antagonists, maintenance, therapeutics, asthma		Biomedicines20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 3
N/A 2
Phase 2 2

By status:

Completed 6
Recruiting 1

By type:

Interventional 6
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 1
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Follow up of Spanish Prospective Asthma and Nasal Polyposis Registry
NCT06163807 — registries, polyps, eosinophils, biomarkers, therapeutics, asthma, nasal polyps, biological products, anti-asthmatic agents		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS